SVSanne C. C. Vincenten

Sanne C. C. Vincenten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sanne C. C. Vincenten has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From Long‐Term to Trial‐Ready: 1.5‐Year Follow‐Up in an Established FSHD Cohort Highlights Limitations of Current Outcome Measures

    by Sjan Teeselink, Sanne C. C. Vincenten, Amir Chaman Baz, Nicol C. Voermans, Nens van Alfen, Baziel G. M. van Engelen, Karlien Mul

    Introduction/Aims: Identifying endpoints that are sensitive to change is crucial for clinical trial design in facioscapulohumeral muscular dystrophy (FSHD). This study adds follow‐up data to a previously published 5‐year natural history study in the same cohort, aiming to correlate short‐term disease progression to longer term follow‐up. Methods: Adult FSHD patients were reassessed 1.5 years after their 5‐year visit. A subgroup underwent trimonthly assessments for 1 year following the 1.5‐year visit. Disease severity scores, motor function measure (MFM), 6‐min walk test (6MWT), antigravity tests (AGTs), and muscle strength by manual muscle testing (MMT) were assessed to determine change over time. Sample sizes were calculated for a hypothetical trial assuming stabilization of the disease as treatment aim. Results: Eighty‐six patients completed both assessments, 30 of whom underwent trimonthly assessments. Over 1.5 years, a small decline was observed in the mean MMT score (median change: −0.2, p < 0.001), and the 6MWT (median change: −14 m, p = 0.009). In the trimonthly subgroup, individual mean MMT scores were variable between visits. Sample size estimates ranged from 16 (MMT of specific muscles) to 1824 participants (MFM) per group depending on the used clinical outcome measure and patient selection. Discussion: This study provides clinically relevant data on short‐term progression in FSHD. The findings confirm the limited responsiveness of clinical outcome measures resulting in large sample size estimates, demonstrate variability of MMT, and highlight the need for multimodal or biomarker‐based endpoints to enable feasible and sensitive clinical trial design.

  • Open Access

    From preconception to parenting: reproductive health and pregnancy care in facioscapulohumeral muscular dystrophy

    by S.C.C. Vincenten, A. Rosenberger, R. Badiani, V.A. Sansone, O.W.H. van der Heijden, L.L. Thornburg

  • Open Access

    Development and Validation of a Deep Learning‐Based Facial Weakness Score for Objective Assessment in Facioscapulohumeral Muscular Dystrophy

    by T. G. J. Loonen, T. C. Ten Harkel, S. C. C. Vincenten, C. G. C. Horlings, C. H. G. Beurskens, S. Knuijt, G. W. A. M. Padberg, B. G. M. van Engelen, T. J. J. Maal, K. Mul

    Introduction/Aims: Facioscapulohumeral muscular dystrophy (FSHD) is a muscle disease that leads, among other manifestations, to facial weakness. This weakness can severely impact communication and quality of life, yet it remains under‐researched with limited objective clinical measures. Current manual scoring methods are subjective and exhibit suboptimal inter‐observer agreement. This study aimed to develop and validate a deep learning‐based facial weakness score (DLFWS) as an objective clinical outcome measure for facial weakness in FSHD. Methods: One hundred and twenty‐two genetically confirmed FSHD patients and 56 controls were recruited. Sixty‐four patients had a 5‐year follow‐up visit. Video recordings of participants performing seven facial exercises, each repeated three times, were analyzed using a convolutional neural network. The deep learning‐based facial weakness score (DLFWS) was trained by comparing start and end frames from these exercises with the manual facial weakness scores (MFWS) assigned by three experienced observers. Pearson correlation coefficients and intraclass correlation coefficients (ICC) were used to evaluate the DLFWS's performance and reliability. Results: The DLFWS showed a strong correlation with the MFWS across exercises, with a mean Pearson correlation of 0.79 and a maximum of 0.85 for individual exercises. The DLFWS demonstrated excellent test–retest reliability, with an ICC of 0.90. Over a 5‐year follow‐up period, no significant progression of facial weakness was detected. Discussion: The DLFWS provides a reliable and objective assessment of facial weakness in FSHD patients. This automated tool holds potential for widespread clinical and research applications, enabling standardized assessment of facial weakness in FSHD.

  • Open Access

    The Facioscapulohumeral Muscular Dystrophy Rasch‐Built Overall Disability Scale (FSHD‐RODS): Longitudinal Assessment of a Disease‐Specific Patient Reported Outcome

    by Sjan Teeselink, Sanne C. C. Vincenten, Nicol C. Voermans, Nens van Alfen, Baziel G. M. van Engelen, Karlien Mul

    Objective: To assess changes in the facioscapulohumeral muscular dystrophy Rasch‐Built Overall Disability Scale (FSHD‐RODS) over 6.5 years in FSHD patients.Methods: FSHD patients of 18 years or older were assessed at baseline (T1) and followed up at 5 years (T2) and 6.5 years (T3). The patient‐reported FSHD‐RODS and Sickness Impact Profile 68 (SIP68) questionnaires were evaluated, alongside the FSHD clinical severity score, FSHD clinical score and Motor Function Measure (MFM). Individual minimal clinically important differences (MCID‐SE) of the FSHD‐RODS were calculated to assess the clinical importance of the change over time. A subgroup analysis included patients eligible for current clinical trials.Results: Sixty‐two patients were included, representing the full disease spectrum. The FSHD‐RODS and SIP68 questionnaire outcomes remained stable, whereas overall disease severity slightly increased (FSHD clinical severity score 6 to 6.5, p < 0.001) and MFM slightly decreased (94% to 91%, p < 0.001). FSHD‐RODS correlated strongly with SIP68, MFM and disease severity (ρ ≥ 0.69). The clinical trial subgroup (n = 33) showed similar results. Ten patients (16%), all with moderate–to‐severe baseline disease (FSHD clinical severity score ≥ 6), showed clinically important deterioration over 6.5 years.Conclusions: FSHD progression is generally slow, with FSHD‐RODS only detecting meaningful decline in moderately to severely affected patients. The ability to compensate for muscle weakness may limit the sensitivity of patient‐reported outcomes like FSHD‐RODS in clinical trials. These findings highlight the need for alternative measures to capture disease progression and treatment effects in FSHD research.


  • Open Access

    A 5‐year natural history cohort of patients with facioscapulohumeral muscular dystrophy determining disease progression and feasibility of clinical outcome assessments for clinical trials

    by Joost Kools, Sanne Vincenten, Baziel G. M. van Engelen, Nicoline B. M. Voet, Ingemar Merkies, Corinne G. C. Horlings, Nicol C. Voermans, K. Mul

    Introduction/Aims: The number of clinical trials in facioscapulohumeral muscular dystrophy (FSHD) is expected to increase in the near future. There is a need for clinical outcome assessments (COAs) that can capture disease progression over the relatively short time span of a clinical trial. In this study, we report the natural progression of FSHD and determine the feasibility of COAs for clinical trials.Methods: Genetically confirmed FSHD patients underwent various COAs at baseline and after 5 years. COAs consisted of the Motor Function Measure (MFM), manual muscle testing using the Medical Research Council score, six‐minute walk test, quantitative muscle strength assessment of the quadriceps muscle, clinical severity score, and FSHD evaluation score (FES). Statistical significance and the minimal clinically important difference (MCID) were calculated and power calculations were performed.Results: One hundred fifty‐four symptomatic FSHD patients were included, with a mean (SD) age of 51.4 (14.6) years old. All COAs showed a minimal, yet statistically significant progression after 5 years. MCID was reached for the MFM Domain 1, MFM total score, and FES. These three COAs showed the lowest sample size requirements for clinical trials (185, 156, and 201 participants per group, respectively, for a trial duration of 2 years).Discussion: The captured FSHD disease progression rate in 5 years was generally minimal. The COAs in this study are not feasible for clinical trials with a duration of 2 years. Extended trial durations or novel outcome assessments might be necessary to improve trial feasibility in FSHD.


  • Open Access

    The other face of facioscapulohumeral muscular dystrophy: Exploring orofacial weakness using muscle ultrasound

    by Sanne C. C. Vincenten, Jeroen L. M. van Doorn, Sjan Teeselink, Nathaniel B. Rasing, George W. Padberg, Nicol C. Voermans, Baziel G. M. van Engelen, Nens van Alfen, Karlien Mul

    Introduction/Aims: One of the most distinct clinical features of facioscapulohumeral muscular dystrophy (FSHD) is facial weakness. It leads to diminished facial expression and functional impairments. Despite its clinical relevance, little else is known about orofacial muscle involvement. We therefore evaluated orofacial muscle involvement in a sizeable cohort of FSHD participants with muscle ultrasound. Methods: Muscle ultrasound images of the following orofacial muscles were scored visually and quantitatively: depressor anguli oris (DAO), orbicularis oris (OO), buccinator, temporalis, masseter, digastric, zygomaticus major and minor bilaterally, and the geniohyoid. Reliability analyses of both visual and quantitative evaluations were performed. Ultrasound results were correlated with other measures: the FSHD clinical score, facial weakness score, and facial function scale. Results: We included 107 FSHD participants (male 54%; age 52 ± 14 years), of whom 92% showed signs of facial weakness. The reliability of visual ultrasound analysis varied widely (κ 0.0–1.0). Quantitative ultrasound reliability was high (intraclass correlation analysis ≥ 0.96). The DAO, buccinator, OO, temporalis, and zygomaticus minor muscles were affected most often (15%–39%). The digastric, geniohyoid, zygomaticus major, and masseter muscles were least often affected (ρ = 0.3–0.7). Discussion: This study adds to the understanding of orofacial weakness in FSHD, confirming the involvement of the muscles of facial expression in FSHD using ultrasound. We showed that orofacial muscle ultrasound is feasible and reliable when quantitatively assessed. Future studies should evaluate orofacial muscle ultrasound longitudinally, alongside clinical and patient‐reported facial weakness outcome measures, to assess their potential as outcome measures.


  • Open Access

    The complementary use of muscle ultrasound and MRI in FSHD: Early versus later disease stage follow-up

    by Sanne C.C. Vincenten, Nicol C. Voermans, Donnie Cameron, Baziel G.M. van Engelen, Nens van Alfen, Karlien Mul


  • Electrodiagnostic studies and new diagnostic modalities for evaluation of peripheral nerve disorders

    by Andrew Hannaford, Elijah Paling, Matthew Silsby, Sanne Vincenten, Nens van Alfen, Neil G. Simon

    Electrodiagnostic studies (EDx) are frequently performed in the diagnostic evaluation of peripheral nerve disorders. There is increasing interest in the use of newer, alternative diagnostic modalities, in particular imaging, either to complement or replace established EDx protocols. However, the evidence to support this approach has not been expansively reviewed. In this paper, diagnostic performance data from studies of EDx and other diagnostic modalities in common peripheral nerve disorders have been analyzed and described, with a focus on radiculopathy, plexopathy, compressive neuropathies, and the important neuropathy subtypes of Guillain‐Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), vasculitic neuropathy and diabetic neuropathy. Overall EDx retains its place as a primary diagnostic modality in the evaluated peripheral nerve disorders. Magnetic resonance imaging and ultrasound have developed important complementary diagnostic roles in compressive and traumatic neuropathies and atypical CIDP, but their value is more limited in other neuropathy subtypes. Identification of hourglass constriction in nerves of patients with neuralgic amyotrophy may have therapeutic implications. Investigation of radiculopathy is confounded by poor correlation between clinical features and imaging findings and the lack of a diagnostic gold standard. There is a need to enhance the literature on the utility of these newer diagnostic modalities.


  • Open Access

    Establishing the role of muscle ultrasound as an imaging biomarker in facioscapulohumeral muscular dystrophy

    by S.C.C. Vincenten, S. Teeselink, N.C. Voermans, B.G.M. van Engelen, K. Mul, N. van Alfen


  • Open Access

    Five‐year follow‐up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: The link to clinical outcome

    by Sanne C.C. Vincenten, Karlien Mul, Daniël van As, Julia J. Jansen, Linda Heskamp, Arend Heerschap, Baziel G.M. van Engelen, Nicol C. Voermans

    Background: It is unclear how changes in quantitative muscle magnetic resonance imaging (MRI) relate to changes in clinical outcome in facioscapulohumeral muscular dystrophy (FSHD), although this information is crucial for optimal use of MRI as imaging biomarker in trials. We therefore assessed muscle MRI and clinical outcome measures in a large longitudinal prospective cohort study.Methods: All patients were assessed by MRI at baseline and at 5‐year follow‐up, employing 2pt‐Dixon and turbo inversion recovery magnitude (TIRM) sequences, after which fat fraction and TIRM positivity of 19 leg muscles were determined bilaterally. The MRI compound score (CoS) was defined as the mean fat fraction of all muscles weighted for cross‐sectional area. Clinical outcome measures included the Ricci‐score, FSHD clinical score (FSHD‐CS), MRC sumscore (MRC‐SS), and motor‐function‐measure (MFM).Results: We included 105 FSHD patients [mean age 54 ± 14 years, median Ricci‐score 7 (range 0–10)]. The median change over 5 years' time in the MRI‐CoS was 2.0% (range −4.6 to +12.1; P < 0.001). The median change over 5 years' time in clinical outcome measures was small in all measures, with z‐scores ranging from 5.0 to 7.2 (P < 0.001). The change in MRI‐CoS correlated with change in FSHD‐CS and Ricci‐score (ρ = 0.25, respectively; ρ = 0.23, P < 0.05). The largest median increase in MRI‐CoS was seen in baseline subgroups with an MRI‐CoS 20–40% (6.1%), with ≥2 TIRM positive muscles (3.5%) or with an FSHD‐CS 5–10 (3.1%).Conclusions: This 5‐year study showed significant changes in MRI and clinical outcome measures and a significant correlation between changes in MRI‐CoS and changes in clinical outcome measures. In addition, we identified subgroups of patients that are most prone to radiological disease progression. This knowledge further establishes quantitative MRI parameters as prognostic biomarkers in FSHD and as efficacy biomarkers in upcoming clinical trials.